|
gptkbp:instanceOf
|
gptkb:drug
antiviral drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AX67
|
|
gptkbp:brand
|
gptkb:Harvoni
|
|
gptkbp:CASNumber
|
1256388-51-8
|
|
gptkbp:combines
|
gptkb:Sofosbuvir
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:discoveredIn
|
2010s
|
|
gptkbp:eliminationHalfLife
|
47 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C49H54F2N8O6
|
|
gptkbp:hasSMILES
|
CC1=CC2=C(C=C1)C=C(C=C2)C3=NC4=C(N3)C=CC(=C4)C5=CC=C(C=C5)C6=NC7=C(C=C6)C=CC(=C7)C8=CC=C(C=C8)C9=NC(=C(C=C9)F)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ledipasvir
|
|
gptkbp:IUPACName
|
(S)-... (truncated for brevity)
|
|
gptkbp:KEGGID
|
D10410
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
NS5A inhibitor
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
N (US)
|
|
gptkbp:proteinBinding
|
99.8%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
34982916
67505836
DB09027
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
headache
insomnia
|
|
gptkbp:UNII
|
505CXM6OHG
|
|
gptkbp:usedFor
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:851199-59-2
|
|
gptkbp:bfsLayer
|
7
|